Iptacopan not checked

Novartis · LNP023

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
13 active
28 in total · 15 in the EU

What this is

How it works
Complement Factor B Inhibitor FDA class
How it’s given
“Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)”In the company’s words, NCT04817618 on ClinicalTrials.gov
Tested for
Atypical Hemolytic Uremic Syndrome (2 trials), C3G, Generalized Myasthenia Gravis, Paroxysmal Nocturnal Hemoglobinuria, IC-MPGN, Primary Immunoglobulin A Nephropathy (IgAN), Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria (PNH) and 5 more
Main trialPhase 3
“The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.”In the company’s words, NCT04817618 on ClinicalTrials.gov
Other names
Iptcaopan · LNP023 · Investigational new drug

Other drugs for Atypical Hemolytic Uremic Syndrome

All 4 drugs for Atypical Hemolytic Uremic Syndrome

Coming up12

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials28

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 29 Jan 2027 Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Phase 3Active, not recruiting 30 Apr 2027 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Phase 3Active, not recruiting 18 Oct 2027 Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 3Recruiting 21 Jul 2028 Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3Recruiting 27 Oct 2028 Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Phase 3Recruiting 28 Jun 2030 Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Phase 3Recruiting 4 Dec 2030 A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Phase 3Recruiting 14 Oct 2031 Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Phase 3Recruiting 16 Jul 2032 Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Phase 3Recruiting 30 May 2036 Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Phase 2Active, not recruiting 30 Dec 2026 Iptacopan in Patients With ANCA Associated Vasculitis
Phase 2Recruiting 27 Nov 2027 Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Phase 3Completed 26 Sep 2022 Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Phase 3Completed 2 Nov 2022 Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
Phase 3Completed 17 Oct 2024 Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
Phase 3Completed 19 Sep 2025 Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Phase 3Completed 11 Apr 2026 Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Phase 2Completed 7 Apr 2020 Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2Completed 22 Apr 2020 Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2Completed 29 Dec 2020 Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Phase 2Completed 23 Apr 2021 Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
Phase 2Completed 24 May 2022 Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2Terminated 20 Jan 2023 Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
Phase 2Terminated 20 Sep 2023 Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
Phase 2Terminated 19 Mar 2026 Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Phase 2Completed 19 Aug 2026 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Phase 1Completed 20 Jun 2022 Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.
Phase 3Authorised not given An open-label, single-arm, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients who have completed a clinical trial (parent study) in the iptacopan pediatric program.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Iptacopan

Following is part of Solo: you see every change to Iptacopan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in